GO:1990081 trimethylamine receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990081 (trimethylamine receptor activity) is a molecular function defined as combining with the biogenic amine trimethylamine to initiate a change in cell activity.
• Trimethylamine (TMA) is a gut microbiota-derived metabolite produced from dietary precursors such as choline, carnitine, and betaine, and it is linked to cardiometabolic and neurological disorders.
• The receptor activity mediates cellular responses to TMA, influencing processes such as inflammation, lipid metabolism, and gut-brain communication.
• Key genes and proteins involved include FMO3, which converts TMA to trimethylamine N-oxide (TMAO), and putative TMA receptors such as TAAR1 and TAAR5, though direct TMA receptor identity remains under investigation.
• Dysregulation of TMA signaling is associated with hypertension, atherosclerosis, hepatic ischemia-reperfusion injury, and metabolic disorders.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect the causal roles of candidate TMA receptor genes in disease.
Description
GO:1990081, trimethylamine receptor activity, is a molecular function term in the Gene Ontology that describes the binding of the biogenic amine trimethylamine (TMA) to a receptor, leading to a change in cell activity. TMA is produced by the gut microbiota through the metabolism of dietary choline, carnitine, and betaine, and it is a precursor to trimethylamine N-oxide (TMAO), a metabolite strongly associated with cardiovascular and metabolic diseases. Understanding this receptor activity is crucial because it represents a direct molecular link between microbial metabolism and host cell signaling. Researchers are increasingly interested in identifying the specific receptors that mediate TMA sensing, as they may serve as therapeutic targets for conditions such as hypertension, atherosclerosis, and neuroinflammatory disorders. The study of GO:1990081 also intersects with broader questions about how gut-derived metabolites influence host physiology through the gut-liver and gut-brain axes.
trimethylamine receptor activity At A Glance
| GO ID | GO:1990081 |
|---|---|
| GO term | trimethylamine receptor activity |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Combining with the biogenic amine trimethylamine to initiate a change in cell activity. |
| Major function | Sensing trimethylamine to initiate cellular signaling. |
| Related metabolite | Trimethylamine (TMA), a gut microbiota-derived biogenic amine. |
| Associated pathways | Gut-liver axis, gut-brain communication, cardiometabolic signaling. |
What Is GO:1990081?
Trimethylamine receptor activity (GO:1990081) is defined as the function of combining with the biogenic amine trimethylamine to initiate a change in cell activity. In other words, it is the ability of a cellular receptor to detect and respond to trimethylamine, thereby triggering downstream signaling events that alter the behavior or state of the cell.
Why Is trimethylamine receptor activity Important in Cell Biology?
Trimethylamine receptor activity is important because it represents a direct molecular interface between gut microbial metabolites and host cell function. TMA, generated by the gut microbiota from dietary precursors, can activate specific receptors to modulate inflammation, lipid metabolism, and neuronal signaling. Dysregulation of this activity has been implicated in hypertension, atherosclerosis, hepatic ischemia-reperfusion injury, and metabolic syndrome. Therefore, understanding GO:1990081 can reveal novel therapeutic targets and biomarkers for these diseases.
• Links gut microbiota-derived trimethylamine to host cell signaling.
• Plays a role in cardiometabolic diseases such as hypertension and atherosclerosis.
• Contributes to gut-brain communication and potential neuroinflammatory processes.
• Influences lipid metabolism through the gut-liver axis.
• May serve as a target for probiotic or dietary interventions.
• Relevant to hepatic ischemia-reperfusion injury and remote organ dysfunction.
• Provides a mechanism for microbial metabolite sensing in host cells.
• Potential biomarker for glycolipid metabolism disorders.
What Happens During trimethylamine receptor activity?
Trimethylamine production by gut microbiota
In simple terms: Gut bacteria make trimethylamine from certain foods.
Dietary choline, carnitine, and betaine are metabolized by gut microbiota to produce trimethylamine (TMA). This TMA can then enter the bloodstream and reach host tissues, where it may interact with specific receptors.
Receptor binding and activation
In simple terms: TMA binds to a receptor on cells, like a key in a lock.
Once TMA reaches a target cell, it can bind to a receptor protein, triggering a conformational change that initiates intracellular signaling. The exact identity of the TMA receptor is not fully resolved, but candidates include trace amine-associated receptors (TAARs) and other G-protein-coupled receptors.
Downstream signaling cascades
In simple terms: The activated receptor sends signals inside the cell.
Receptor activation by TMA can lead to changes in second messenger levels, kinase cascades, and gene expression, ultimately altering cell activity. These signaling events may affect inflammatory pathways, lipid metabolism, and neuronal function.
Physiological outcomes
In simple terms: The cell responds, affecting body functions.
The cellular response to TMA can influence blood pressure regulation, immune responses, and metabolic homeostasis. In the gut-liver axis, TMA signaling may contribute to hepatic injury and repair processes.
Key Genes Involved in GO:1990081 trimethylamine receptor activity
The following genes and proteins are implicated in trimethylamine receptor activity and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FMO3 | Converts TMA to TMAO | Key enzyme in TMA metabolism; linked to cardiometabolic disease |
| TAAR1 | Putative receptor for trace amines | Candidate TMA receptor; involved in neurological signaling |
| TAAR5 | Putative receptor for trimethylamine | May mediate TMA sensing in olfactory and other tissues |
| TAAR2 | Trace amine receptor | Potential TMA receptor; role in immune modulation |
| TAAR6 | Trace amine receptor | Candidate for TMA binding; under investigation |
| TAAR8 | Trace amine receptor | Possible involvement in TMA signaling |
| TAAR9 | Trace amine receptor | Potential TMA receptor; expressed in various tissues |
| CHKA | Choline kinase | Involved in choline metabolism, affecting TMA production |
| CHKB | Choline kinase beta | Choline metabolism; influences TMA precursor availability |
| SLC44A1 | Choline transporter | Uptake of choline for TMA synthesis |
| SLC44A2 | Choline transporter | Choline transport; impacts TMA generation |
| SLC22A1 | Organic cation transporter | May transport TMA or its precursors |
| SLC22A2 | Organic cation transporter | Potential TMA transport |
| SLC22A3 | Organic cation transporter | Involved in TMA uptake in tissues |
| GPRC6A | G-protein coupled receptor | Candidate receptor for TMA-like amines |
| ADRA1A | Alpha-1 adrenergic receptor | May crosstalk with TMA signaling |
| ADRB2 | Beta-2 adrenergic receptor | Potential downstream target of TMA signaling |
How Is trimethylamine receptor activity Regulated?
The activity of trimethylamine receptor is regulated at multiple levels. The availability of TMA is controlled by gut microbial composition and dietary intake of precursors such as choline and carnitine. Host factors, including the expression of FMO3, which converts TMA to TMAO, can modulate the concentration of TMA available to bind receptors. Additionally, receptor expression levels and post-translational modifications may influence sensitivity to TMA. Inflammatory states and metabolic disorders can alter the expression of candidate receptors, thereby affecting signaling.
trimethylamine receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FMO3 | Atherosclerosis, cardiovascular disease | FMO3 knockout mouse; overexpression in hepatocytes |
| TAAR5 | Neuroinflammation, olfactory dysfunction | TAAR5 knockout mouse; neuronal cell lines |
| TAAR1 | Schizophrenia, metabolic syndrome | TAAR1 knockout mouse; point mutation models |
| SLC22A3 | Hypertension, cardiac hypertrophy | SLC22A3 knockout rat; overexpression in cardiomyocytes |
| CHKA | Metabolic disorders, cancer | CHKA knockout cell lines; knock-in of mutant alleles |
Cardiometabolic diseases
Trimethylamine receptor activity is implicated in hypertension and atherosclerosis. Elevated TMAO, derived from TMA, is associated with increased cardiovascular risk. TMA signaling may promote endothelial dysfunction and inflammation, contributing to disease progression.
Hepatic ischemia-reperfusion injury
The gut-liver axis plays a critical role in hepatic ischemia-reperfusion injury. TMA and its receptor activity may influence liver inflammation and injury through microbiota-derived signals.
Neurological and neuroinflammatory disorders
TMA can cross the blood-brain barrier and potentially activate receptors in the central nervous system, affecting neuronal function and neuroinflammation. This links GO:1990081 to conditions such as neurodegeneration and mood disorders.
Metabolic disorders
Disruptions in TMA signaling are associated with glycolipid metabolism disorders and obesity-related pathways. The receptor activity may modulate lipid handling and insulin sensitivity.
From trimethylamine receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FMO3 regulate TMA receptor signaling? | FMO3 knockout mouse or cell line |
| What is the role of TAAR5 in TMA sensing? | TAAR5 knockout mouse or CRISPR knockout cell line |
| Can point mutations in TAAR1 alter TMA binding? | Point mutation knock-in cell lines |
| Does overexpression of SLC22A3 affect TMA uptake? | SLC22A3 overexpression cell model |
| How does TMA receptor activity affect lipid metabolism? | Knockout and overexpression models in hepatocytes |
| What is the impact of TMA receptor on blood pressure? | Knockout rat models with telemetry |
How to Study the trimethylamine receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality for TMA response | Identify novel receptor components |
| RNA-seq | Transcriptional changes | Pathway analysis after TMA treatment |
| Proteomics | Protein abundance and interactions | Detect receptor complexes |
| Metabolomics | TMA and TMAO levels | Quantify metabolite flux |
| Reporter assays | Receptor activation | High-throughput screening |
| Imaging | Cellular localization and signaling | Live-cell dynamics |
| Patch-clamp | Ion channel activity | Electrophysiological response |
| Flow cytometry | Cell surface receptor expression | Sort receptor-positive cells |
CRISPR-Cas9 knockout screening
Genome-wide CRISPR knockout screens can identify genes essential for TMA receptor activity. By treating cells with TMA and measuring downstream signaling, researchers can uncover novel components of the pathway.
Transcriptomics and RNA-seq
RNA sequencing can reveal changes in gene expression upon TMA stimulation, highlighting pathways regulated by trimethylamine receptor activity.
Proteomics and metabolomics
Mass spectrometry-based proteomics and metabolomics can quantify TMA and TMAO levels and identify protein interactions with candidate receptors.
Imaging and reporter assays
Fluorescent or luminescent reporter assays can monitor receptor activation in real time. Imaging techniques can visualize TMA-induced signaling in live cells.
How CRISPR Can Be Used to Study GO:1990081 trimethylamine receptor activity
Knockout
CRISPR knockout of candidate genes such as FMO3, TAAR5, or SLC22A3 can abolish TMA receptor activity, allowing researchers to test causality in disease models.
Point Mutation
Introducing point mutations in receptor genes can mimic human polymorphisms and assess their impact on TMA binding and signaling.
Knock-in
Knock-in of tagged receptors (e.g., HA or GFP) enables visualization and pull-down of receptor complexes under native conditions.
Overexpression
Overexpression of candidate receptors in cell lines can enhance TMA sensitivity and facilitate drug screening.
How EDITGENE Supports trimethylamine receptor activity Research
Researchers studying trimethylamine receptor activity-related genes often need to determine whether a candidate gene is causally involved in TMA sensing and downstream pathology. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for trimethylamine receptor activity research.
Frequently Asked Questions About trimethylamine receptor activity
What is trimethylamine receptor activity?
Trimethylamine receptor activity (GO:1990081) is a molecular function where a receptor binds trimethylamine to trigger changes in cell activity.
What genes are involved in trimethylamine receptor activity?
Genes such as FMO3, TAAR1, TAAR5, and SLC22A3 are implicated in trimethylamine metabolism and sensing.
How is trimethylamine produced in the body?
Gut microbiota produce trimethylamine from dietary choline, carnitine, and betaine.
What diseases are linked to trimethylamine receptor activity?
It is linked to hypertension, atherosclerosis, hepatic ischemia-reperfusion injury, and neuroinflammatory disorders.
Can CRISPR be used to study trimethylamine receptor activity?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect gene function in TMA signaling.
What is the role of FMO3 in trimethylamine receptor activity?
FMO3 converts trimethylamine to trimethylamine N-oxide, thereby regulating the availability of TMA for receptor binding.
How does trimethylamine affect the gut-brain axis?
TMA can cross the blood-brain barrier and potentially activate receptors in the brain, influencing neuronal function.
What are the research methods to study trimethylamine receptor activity?
Methods include CRISPR screening, RNA-seq, proteomics, metabolomics, and reporter assays.
Is trimethylamine receptor activity a drug target?
Yes, modulating this activity could offer therapeutic strategies for cardiometabolic and neurological diseases.
What cell models are available for trimethylamine receptor research?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for genes like FMO3 and TAAR5.
Conclusion
Trimethylamine receptor activity (GO:1990081) is a critical molecular function that bridges gut microbial metabolism and host cell signaling. Its role in cardiometabolic, hepatic, and neurological diseases underscores its potential as a therapeutic target. Leveraging CRISPR-based models and multi-omics approaches will further elucidate the mechanisms and identify novel interventions.
References
- 1. de Vos WM et al.. 2022. Gut microbiome and health: mechanistic insights.. Gut 71(5):1020-1032 PMID: 35105664
- 2. Nabavi-Rad A et al.. 2022. The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.. Gut Microbes 14(1):2108655 PMID: 35951774
- 3. de Oliveira THC et al.. 2026. The gut-liver axis in hepatic ischemia-reperfusion injury: from microbiota dysbiosis to remote organ dysfunction.. J Gastrointest Surg 30(11):102568 PMID: 42648431
- 4. Cao S et al.. 2024. Effects of Saponins on Lipid Metabolism: The Gut-Liver Axis Plays a Key Role.. Nutrients 16(10) PMID: 38794751
- 5. O'Donnell JA et al.. 2023. The gut microbiome and hypertension.. Nat Rev Nephrol 19(3):153-167 PMID: 36631562
- 6. Guan B et al.. 2022. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.. Acta Pharm Sin B 12(5):2129-2149 PMID: 35646540
- 7. Ahmed H et al.. 2022. Microbiota-derived metabolites as drivers of gut-brain communication.. Gut Microbes 14(1):2102878 PMID: 35903003
- 8. Fang X et al.. 2022. Advances in multi-omics study of biomarkers of glycolipid metabolism disorder.. Comput Struct Biotechnol J 20:5935-5951 PMID: 36382190
